

# Jeffrey J Pu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1196167/publications.pdf>

Version: 2024-02-01

72  
papers

2,073  
citations

448610

19  
h-index

274796

44  
g-index

73  
all docs

73  
docs citations

73  
times ranked

3174  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mantle cell lymphoma management trends and novel agents: where are we going?. Therapeutic Advances in Hematology, 2022, 13, 204062072210807.	1.1	8
2	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Advances, 2022, 6, 4553-4557.	2.5	22
3	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K $\delta$ inhibitor therapy. Blood, 2021, 137, 2817-2826.	0.6	38
4	Resolution of Chronic Immune Thrombocytopenia Purpura after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma. Journal of Medical Cases, 2021, 12, 37-40.	0.4	0
5	Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. Journal of Hematology and Oncology, 2021, 14, 66.	6.9	35
6	CD70 $\alpha$ -targeting CAR $\alpha$ T cells have potential activity against CD19 $\alpha$ -negative B $\alpha$ cell Lymphoma. Cancer Communications, 2021, 41, 925-929.	3.7	13
7	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood, 2021, 138, 1768-1773.	0.6	53
8	PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression. Scientific Reports, 2021, 11, 19022.	1.6	3
9	Impacts of Total Body Irradiation in Allogeneic Umbilical Cord Blood Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 4852-4852.	0.6	0
10	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood, 2020, 136, 1134-1143.	0.6	248
11	Alternative Polyadenylation: a new frontier in post transcriptional regulation. Biomarker Research, 2020, 8, 67.	2.8	48
12	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real $\alpha$ world setting. A GIMEMA $\alpha$ ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	1.3	12
13	<p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. Blood and Lymphatic Cancer: Targets and Therapy, 2020, Volume 10, 1-5.	1.2	1
14	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clinical Cancer Research, 2020, 26, 3589-3596.	3.2	80
15	Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. Blood, 2020, 136, 39-41.	0.6	13
16	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	0.6	2
17	Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. Cancer Biology and Therapy, 2019, 20, 1389-1397.	1.5	6
18	Phase 1 $\alpha$ 2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B $\alpha$ cell non $\alpha$ Hodgkin lymphoma and previously untreated mantle cell lymphoma. British Journal of Haematology, 2019, 186, 845-854.	1.2	18

#	ARTICLE	IF	CITATIONS
19	Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study. <i>British Journal of Haematology</i> , 2019, 186, e130-e133.	1.2	9
20	Ruxolitinib Maintenance Post Myelofibrosis Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S123.	2.0	4
21	Mantle cell lymphoma and its management: where are we now?. <i>Experimental Hematology and Oncology</i> , 2019, 8, 2.	2.0	28
22	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	0.6	4
23	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	1.7	329
24	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene. <i>Gene</i> , 2018, 638, 20-25.	1.0	87
25	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. <i>Cell Cycle</i> , 2018, 17, 468-478.	1.3	34
26	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	2.0	52
27	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	1.7	135
28	Impact of ruxolitinib in myelofibrosis post allogeneic stem cell transplant: A pilot study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7071-7071.	0.8	1
29	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K $\gamma$ inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7530-7530.	0.8	5
30	PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12092-12092.	0.8	0
31	Pign Suppresses CIN and Leukemia Progression Via Regulation of the Spindle Assembly Checkpoint. <i>Blood</i> , 2018, 132, 2792-2792.	0.6	0
32	PIG-a Gene Expression Deficiency Association with Reduced DNA Damage Checkpoint Response and Activation. <i>Blood</i> , 2018, 132, 3875-3875.	0.6	0
33	The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation—a Collateral Study on VCR Phase I Trial. <i>Blood</i> , 2018, 132, 5295-5295.	0.6	0
34	Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. <i>Annals of Oncology</i> , 2017, 28, 1050-1056.	0.6	187
35	Primary myelofibrosis and its targeted therapy. <i>Annals of Hematology</i> , 2017, 96, 531-535.	0.8	6
36	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. <i>Oncotarget</i> , 2017, 8, 29887-29905.	0.8	9

#	ARTICLE	IF	CITATIONS
37	KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.. Journal of Clinical Oncology, 2017, 35, TPS7569-TPS7569.	0.8	0
38	Abstract 5713: PIGN gene expression aberration weakens chromosomal stability via altering its interaction with the spindle assembly checkpoint protein complex during leukemogenesis. , 2017, , .		0
39	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood, 2016, 128, 2199-2205.	0.6	166
40	Unrelated Donor Umbilical Cord Blood Transplantation with and without Total Body Irradiation: A Single-Center Experience. Biology of Blood and Marrow Transplantation, 2016, 22, S374-S375.	2.0	0
41	Paraneoplastic cerebellar degeneration as an early sign of classical Hodgkin lymphoma. Annals of Hematology, 2016, 95, 511-513.	0.8	3
42	The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma. Blood, 2016, 128, 1792-1792.	0.6	5
43	Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma. Blood, 2016, 128, 2759-2759.	0.6	1
44	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. Blood, 2016, 128, 3222-3222.	0.6	16
45	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. Blood, 2016, 128, 4400-4400.	0.6	2
46	Advances and perspectives on cellular therapy in acquired bone marrow failure diseases. World Journal of Hematology, 2016, 5, 31.	0.1	0
47	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. Blood, 2015, 126, 719-719.	0.6	10
48	Unrelated donor umbilical cord blood transplantation with and without total body irradiation: A single-center experience.. Journal of Clinical Oncology, 2015, 33, e18001-e18001.	0.8	0
49	Successful discontinuation of eculizumab therapy in a patient with aHUS. Annals of Hematology, 2014, 93, 1423-1425.	0.8	19
50	Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. Experimental Hematology, 2014, 42, 857-861.e1.	0.2	18
51	Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkinâ€™s Lymphoma and Previously Untreated Mantle Cell Lymphoma. Blood, 2014, 124, 1714-1714.	0.6	7
52	Utilization of Total Body Irradiation Is Not Necessary for Unrelated Donor Umbilical Cord Blood Transplants: a Single-Center Experience. Blood, 2014, 124, 5844-5844.	0.6	0
53	Screen of Small Molecule ONC201/TIC10 Identifies Single Agent Activity and Combinatorial Efficacy with Bortezomib, Rituximab or Dexamethasone in Killing of Acute Lymphoblastic Leukemia Cells. Blood, 2014, 124, 5233-5233.	0.6	0
54	Synergistic Effect of Quinacrine with Chemotherapeutics or TRAIL in Hematopoietic Malignant Cells. Blood, 2014, 124, 5239-5239.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Caspase-Dependent Anti-Tumor Effects of ONC201/TIC10 on Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 5224-5224.	0.6	0
56	Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins. <i>Blood</i> , 2014, 124, 5237-5237.	0.6	1
57	Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders. <i>Experimental Hematology</i> , 2013, 41, 808-816.	0.2	10
58	The origin of GPI-AP deficient cells in MDS, MPD, and aplastic anemia and its significance in predicting leukemic transformation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7032-7032.	0.8	1
59	Comparison Of Lymphocytic Immune Profiles Of Aplastic Anemia and Hypocellular Myelodysplastic Syndrome. <i>Blood</i> , 2013, 122, 3719-3719.	0.6	0
60	The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. <i>Haematologica</i> , 2012, 97, 1225-1233.	1.7	19
61	Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside. <i>Clinical and Translational Science</i> , 2011, 4, 219-224.	1.5	64
62	Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. <i>European Journal of Haematology</i> , 2011, 87, 37-45.	1.1	68
63	Gallbladder carcinosarcoma. <i>BMJ Case Reports</i> , 2011, 2011, bcr0520103009-bcr0520103009.	0.2	16
64	Relevance of PIG-A mutation in aplastic anemia and myelodysplastic syndromes.. <i>Journal of Clinical Oncology</i> , 2011, 29, 6596-6596.	0.8	0
65	Natural History of Paroxysmal Nocturnal Hemoglobinuria Clones In Patients Presenting as Aplastic Anemia. <i>Blood</i> , 2010, 116, 4428-4428.	0.6	0
66	Relevance of Minor PIG-A Mutations In Acquired Aplastic Anemia and Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4433-4433.	0.6	0
67	Spontaneously arising red cells with a McLeod-like phenotype in normal donors. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009, 671, 1-5.	0.4	3
68	Spontaneously Arising Red Cells with a McLeod-Like Phenotype in Normal Donors. <i>Blood</i> , 2008, 112, 2883-2883.	0.6	0
69	Onset of expression of the components of the Kell blood group complex. <i>Transfusion</i> , 2005, 45, 969-974.	0.8	14
70	CLONING AND STRUCTURAL CHARACTERIZATION OF ECTACC, A NEW MEMBER OF THE TRANSFORMING ACIDIC COILED COIL (TACC) GENE FAMILY: cDNA SEQUENCE AND EXPRESSION ANALYSIS IN HUMAN MICROVASCULAR ENDOTHELIAL CELLS. <i>Cytokine</i> , 2001, 13, 129-137.	1.4	22
71	The mouse Kell blood group gene ( <i>Kel</i> ): cDNA sequence, genomic organization, expression, and enzymatic function. <i>Immunogenetics</i> , 2000, 52, 53-62.	1.2	18
72	The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. <i>Gene</i> , 1997, 197, 177-187.	1.0	99